ImmunoMet Therapeutics, Inc. Email Format

Biotechnology ResearchTexas, United States2-10 Employees

ImmunoMet Therapeutics, Inc. is a clinical-stage biotechnology company focused on targeting cellular metabolism to develop therapies for fibrosis and cancer. Its lead program, IM156, is a protein complex 1 inhibitor that disrupts the mitochondrial oxidative phosphorylation pathway to slow abnormal cell growth in fibrotic tissue and in certain cancers. IM156 has completed Phase 1 with favorable tolerability, and the company has outlined plans to advance to a Phase 2 proof-of-concept study in idiopathic pulmonary fibrosis. The organization operates within the biotechnology research arena, concentrating on anti-fibrotic and anti-tumor indications. Based in Houston, Texas, ImmunoMet was founded in 2015 as a spin-off from HanAll Biopharma, a Korean midsized public company, and maintains a relatively small team. In November 2022, the company announced that the first patient had been dosed in a Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel for frontline treatment of advanced pancreatic cancer.

Get verified ImmunoMet Therapeutics, Inc. emails free

Company overview Employee directory